Review spotlights retinoic acid as a male fertility target
Bottom line
A new review in Animals argues that retinoic acid, a vitamin A–derived signaling molecule, sits at the center of male reproductive biology, shaping spermatogonial differentiation, meiotic entry, and later stages of sperm development. The paper, by Vanmathy and Ramanathan Kasimanickam, frames that biology through a One Health lens, linking basic reproductive science across species with the search for nonhormonal male contraceptives. That translational angle matters because retinoic acid receptor-alpha, or RAR-α, is already being pursued as a drug target: the oral candidate YCT-529 has shown reversible suppression of spermatogenesis in preclinical work and reported first-in-human phase 1 safety and pharmacokinetic data in 2025. (nature.com)
Why it matters: For veterinary professionals, the review is less about an immediate practice change than about a biologic pathway with broad relevance to fertility, toxicology, comparative reproduction, and future population-control tools. Retinoic acid signaling has been studied in dogs, including earlier work from the same research group showing modulation of meiosis-associated and retinoid-pathway genes in canine testis models, which supports the idea that companion animal and livestock species can inform, and be informed by, contraceptive innovation in people. The broader literature also shows that disrupted retinoid signaling can arrest spermatogenesis, while selective pathway targeting may offer a reversible, nonhormonal strategy. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for whether RAR-α–targeting compounds move beyond early human safety studies and whether veterinary researchers translate this pathway into species-specific fertility control or infertility applications. (nature.com)
Key facts
- Study type
- Review published in Animals
- Topic
- Retinoic acid signaling in male reproductive biology
- Main biological roles
- Spermatogonial differentiation, meiotic entry, and later sperm development
- Framework
- One Health
- Drug target
- RAR-α
- Candidate
- YCT-529
- Phase 1a study
- 16 healthy vasectomized men
- Phase 1a findings
- Safety, tolerability, and pharmacokinetics were assessed, and hormone levels remained consistent after dosing
- Veterinary relevance
- Earlier canine testis studies showed retinoic acid pathway modulation altered meiosis-associated gene expression
A review newly published in Animals puts retinoic acid signaling back in focus as one of the core control systems in male fertility, and it does so with an explicitly translational message: the same pathway that governs germ cell development may also support the next wave of nonhormonal male contraceptives. The authors, Vanmathy and Ramanathan Kasimanickam, position retinoic acid biology within a One Health framework, connecting reproductive mechanisms across species rather than treating human and veterinary fertility research as separate tracks. That framing lands at a moment when retinoic acid receptor-alpha is moving from theory into early clinical development as a contraceptive target. (nature.com)
The scientific backdrop is well established. Retinoic acid, the active metabolite of vitamin A, is required for normal spermatogenesis, and decades of animal and molecular work have shown that disruption of this pathway can halt germ cell differentiation and contribute to sterility. Reviews and mechanistic studies have tied retinoic acid signaling to key checkpoints including spermatogonial differentiation, meiotic initiation, and Sertoli cell–germ cell coordination, while RAR-α knockout models helped validate the receptor as a particularly attractive contraceptive target. (pubmed.ncbi.nlm.nih.gov)
That helps explain why the review’s contraceptive angle is drawing attention. In 2025, investigators reported phase 1a data for YCT-529, an oral, nonhormonal RAR-α antagonist being developed for male contraception. In that first-in-human single-ascending-dose study, 16 healthy vasectomized men received doses from 10 mg to 180 mg; the study primarily assessed safety, tolerability, and pharmacokinetics, and hormone levels remained consistent after dosing. The same development program has also published preclinical evidence in mice and nonhuman primates showing dose-dependent impairment of spermatogenesis with recovery after treatment cessation, supporting the idea that retinoid-pathway inhibition could be reversible. (nature.com)
For veterinary readers, the One Health claim is more than rhetorical. The Kasimanickam group has published earlier canine testis studies showing that exogenous retinoic acid, CYP26B1 inhibition, and RAR-α antagonism can alter expression of STRA8 and other meiosis-associated genes in dog testicular tissue. Additional work from the group mapped expression of CYP26b1 and related retinoic acid signaling molecules across postnatal dog testis development. Taken together, those studies suggest that companion animal models may be useful both for understanding male infertility biology and for evaluating fertility-control strategies that depend on conserved retinoid pathways. (pubmed.ncbi.nlm.nih.gov)
Industry and academic commentary broadly supports the significance of this direction, while also underscoring that the field is still early. A 2026 review of novel male contraceptives noted that nonhormonal methods, including a retinoic acid receptor antagonist, have now entered first-in-human testing. Another recent review described RAR-α as a compelling genetically and pharmacologically validated target, but the literature also continues to flag the challenge of balancing efficacy with off-target effects because retinoid signaling has roles beyond the testis. That tension, between pathway specificity and systemic safety, remains central to whether these candidates can advance. (tandfonline.com)
Why it matters: For veterinary professionals, this is a research story with several practical edges. First, it reinforces retinoid signaling as a relevant pathway in male infertility, developmental toxicology, and comparative theriogenology. Second, it may help shape future fertility-control tools for dogs, cats, livestock, or wildlife if species-specific delivery and safety hurdles can be solved. Third, it highlights how veterinary reproductive models can contribute to drug discovery that ultimately serves both animal and human health. In that sense, the review’s One Health framing is a reasonable inference from the underlying literature, not just a branding exercise. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next milestones are likely to come from clinical development of RAR-α antagonists such as YCT-529, along with follow-on studies that better define reversibility, chronic safety, and species-specific biology. On the veterinary side, watch for new work applying retinoic acid pathway modulation to fertility control, infertility treatment, or reproductive toxicology in companion animals and livestock. (nature.com)